Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer

被引：0
|
作者：
Hiroyuki Okuyama
Yoshinori Kagawa
Toshiki Masuishi
Saori Mishima
Hiromichi Shirasu
Koji Ando
Satoshi Yuki
Kei Muro
Takayuki Yoshino
Kentaro Yamazaki
Eiji Oki
Yoshito Komatsu
Akihito Tsuji
机构：
[1] Kagawa University,Department of Clinical Oncology, Faculty of Medicine
[2] Kansai Rosai Hospital,Department of Colorectal Surgery
[3] Aichi Cancer Center Hospital,Department of Clinical Oncology
[4] National Cancer Center Hospital East,Department of Gastrointestinal Oncology
[5] Shizuoka Cancer Center,Division of Gastrointestinal Oncology
[6] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[7] Hokkaido University Hospital,Department of Gastroenterology and Hepatology
[8] Hokkaido University Hospital Cancer Center,Department of Cancer Chemotherapy
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Infusion reaction; Ramucirumab; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2025 / 2028
页数：3
相关论文
共 50 条
  • [1] Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer
    Okuyama, Hiroyuki
    Kagawa, Yoshinori
    Masuishi, Toshiki
    Mishima, Saori
    Shirasu, Hiromichi
    Ando, Koji
    Yuki, Satoshi
    Muro, Kei
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Oki, Eiji
    Komatsu, Yoshito
    Tsuji, Akihito
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2025 - 2028
  • [2] Metastatic colorectal Cancer Ramucirumab plus FOLFIRI as Second Line Treatment
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1145 - 1145
  • [3] Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
    Tomoyasu Yoshihiro
    Hitoshi Kusaba
    Akitaka Makiyama
    Kazuma Kobayashi
    Masato Uenomachi
    Mamoru Ito
    Yasuhiro Doi
    Kenji Mitsugi
    Tomomi Aikawa
    Kotoe Takayoshi
    Taito Esaki
    Hozumi Shimokawa
    Kenji Tsuchihashi
    Hiroshi Ariyama
    Koichi Akashi
    Eishi Baba
    International Journal of Clinical Oncology, 2019, 24 : 508 - 515
  • [4] Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
    Yoshihiro, Tomoyasu
    Kusaba, Hitoshi
    Makiyama, Akitaka
    Kobayashi, Kazuma
    Uenomachi, Masato
    Ito, Mamoru
    Doi, Yasuhiro
    Mitsugi, Kenji
    Aikawa, Tomomi
    Takayoshi, Kotoe
    Esaki, Taito
    Shimokawa, Hozumi
    Tsuchihashi, Kenji
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 508 - 515
  • [5] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Suzuki, Takeshi
    Shinozaki, Eiji
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Ichimura, Takashi
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Yamaguchi, Kensei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 307 - 313
  • [6] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Takeshi Suzuki
    Eiji Shinozaki
    Hiroki Osumi
    Izuma Nakayama
    Yumiko Ota
    Takashi Ichimura
    Mariko Ogura
    Takeru Wakatsuki
    Akira Ooki
    Daisuke Takahari
    Mitsukuni Suenaga
    Keisho Chin
    Kensei Yamaguchi
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 307 - 313
  • [7] Therapeutic response to ramucirumab plus folfiri in patients with metastatic gastric cancer
    Rezvani, Hamid
    Haghighi, Shirin
    Ghobakhlou, Mehdi
    Ataei, Elnaz
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (09) : 5166 - 5169
  • [8] FOLFIRI plus bevacizumab versus FOLFIRI plus ramucirumab as second-line chemotherapy for metastatic colorectal cancer in the real-world
    Shimura, T.
    Kitagawa, M.
    Sugimura, N.
    Fukusada, S.
    Tanaka, M.
    Kataoka, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1439 - S1439
  • [9] The efficacy and safety of Ramucirumab and FOLFIRI for the treatment of advanced/ recurred colorectal cancer in late line
    Osawa, Hiroshi
    Ding, Ye
    Minakata, Kunihiko
    Goto, Hiroaki
    Handa, Naoko
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy
    Wilke, H.
    Siena, S.
    Loos, A. H.
    Berghoff, K.
    Kohne, C.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345